Editöre Mektup
BibTex RIS Kaynak Göster

Myelodysplastic Syndrome and Artificial Intelligence

Yıl 2024, Cilt: 15 Sayı: 4, 680 - 680, 31.12.2024
https://doi.org/10.18663/tjcl.1577122

Öz

In the artificial intelligence that will be used in the diagnosis of MDS, the accuracy rate will increase if the database includes all the factors that are effective in the diagnosis and risk classification as much as possible. Artificial intelligence applications that will be implemented using a database that includes as many factors as possible can guide the clinician in the diagnosis of MDS and even in individual treatment choices. Studies with as many patients as possible are needed on this subject.

Etik Beyan

none

Destekleyen Kurum

none

Teşekkür

none

Kaynakça

  • Karel D, Valburg C, Woddor N, Nava VE, Aggarwal A. Myelodysplastic Neoplasms (MDS): The Current and Future Treatment Landscape. Curr Oncol. 2024;31:1971-93.
  • Sabile JM, Kaempf A, Tomic K, Manu GP, Swords R, Migdady Y. A retrospective validation of the IPSS-M molecular score in primary and therapy-related myelodysplastic syndromes (MDS). Leuk Lymphoma. 2023;64:1689-94.
  • Elshoeibi AM, Badr A, Elsayed B, Metwally O, Elshoeibi R, Elhadary MR, et al. Integrating AI and ML in Myelodysplastic Syndrome Diagnosis: State-of-the-Art and Future Prospects. Cancers. 2023;16: 65.

Myelodisplastik Sendrom ve Yapay Zeka

Yıl 2024, Cilt: 15 Sayı: 4, 680 - 680, 31.12.2024
https://doi.org/10.18663/tjcl.1577122

Öz

MDS tanısında kullanılacak olan yapay zekada veri tabanının tanıda ve risk sınıflamasında etkili tüm faktörleri olabildiğince içermesi doğruluk oranını yükselecektir. Olabildiğince çok faktörü barındıran veri tabanı kullanılarak uygulanacak olan yapay zeka uygulamaları MDS tanısında ve hatta bireysel tedavi seçimlerinde klinisyene yol gösterici olabilir. Bu konu ile ilgili hasta sayısının olabildiğince çok olduğu çalışmalara ihtiyaç vardır.

Kaynakça

  • Karel D, Valburg C, Woddor N, Nava VE, Aggarwal A. Myelodysplastic Neoplasms (MDS): The Current and Future Treatment Landscape. Curr Oncol. 2024;31:1971-93.
  • Sabile JM, Kaempf A, Tomic K, Manu GP, Swords R, Migdady Y. A retrospective validation of the IPSS-M molecular score in primary and therapy-related myelodysplastic syndromes (MDS). Leuk Lymphoma. 2023;64:1689-94.
  • Elshoeibi AM, Badr A, Elsayed B, Metwally O, Elshoeibi R, Elhadary MR, et al. Integrating AI and ML in Myelodysplastic Syndrome Diagnosis: State-of-the-Art and Future Prospects. Cancers. 2023;16: 65.
Toplam 3 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Konular Hematolojik Tümörler
Bölüm Editöre Mektup
Yazarlar

Fatma Yılmaz 0000-0001-6112-3950

Yayımlanma Tarihi 31 Aralık 2024
Gönderilme Tarihi 31 Ekim 2024
Kabul Tarihi 26 Kasım 2024
Yayımlandığı Sayı Yıl 2024 Cilt: 15 Sayı: 4

Kaynak Göster

APA Yılmaz, F. (2024). Myelodysplastic Syndrome and Artificial Intelligence. Turkish Journal of Clinics and Laboratory, 15(4), 680-680. https://doi.org/10.18663/tjcl.1577122
AMA Yılmaz F. Myelodysplastic Syndrome and Artificial Intelligence. TJCL. Aralık 2024;15(4):680-680. doi:10.18663/tjcl.1577122
Chicago Yılmaz, Fatma. “Myelodysplastic Syndrome and Artificial Intelligence”. Turkish Journal of Clinics and Laboratory 15, sy. 4 (Aralık 2024): 680-80. https://doi.org/10.18663/tjcl.1577122.
EndNote Yılmaz F (01 Aralık 2024) Myelodysplastic Syndrome and Artificial Intelligence. Turkish Journal of Clinics and Laboratory 15 4 680–680.
IEEE F. Yılmaz, “Myelodysplastic Syndrome and Artificial Intelligence”, TJCL, c. 15, sy. 4, ss. 680–680, 2024, doi: 10.18663/tjcl.1577122.
ISNAD Yılmaz, Fatma. “Myelodysplastic Syndrome and Artificial Intelligence”. Turkish Journal of Clinics and Laboratory 15/4 (Aralık 2024), 680-680. https://doi.org/10.18663/tjcl.1577122.
JAMA Yılmaz F. Myelodysplastic Syndrome and Artificial Intelligence. TJCL. 2024;15:680–680.
MLA Yılmaz, Fatma. “Myelodysplastic Syndrome and Artificial Intelligence”. Turkish Journal of Clinics and Laboratory, c. 15, sy. 4, 2024, ss. 680-, doi:10.18663/tjcl.1577122.
Vancouver Yılmaz F. Myelodysplastic Syndrome and Artificial Intelligence. TJCL. 2024;15(4):680-.


e-ISSN: 2149-8296

The content of this site is intended for health care professionals. All the published articles are distributed under the terms of

Creative Commons Attribution Licence,

which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.